Gastric cancer – a heterogeneous disease in need of a refined approach

At a Presidential Symposium during ESMO 2012 in Vienna, Professor Florian Lordick from the University Clinic Leipzig and the University Cancer Center (UCCL), Leipzig, Germany, presented data from the open-label randomized, controlled Phase 3 EXPAND trial of cetuximab in combination with capecitabine and cisplatin as first-line treatment for advanced gastric cancer (LBA3). Read more here.